Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 13 Sept 2026Clinical review pending
Saved on this device
!
Acute neurological or device complication
New severe headache, focal deficit, seizure, reduced consciousness, fever, wound drainage or rapidly spreading erythema after DBS can indicate haemorrhage, stroke, infection or hardware-related intracranial disease.
Action: Stop routine programming, assess ABC and neurology, contact the implanting neurosurgical and movement-disorder service urgently, and obtain cause-directed imaging and cultures without manipulating exposed hardware.
Synopsis
Explain disease-specific selection, stereotactic implantation and programming, realistic benefits and limitations, device safety, urgent complications, and the long-term multidisciplinary work required after deep-brain stimulation.
DBS delivers adjustable electrical stimulation through stereotactically implanted intracranial leads connected to a pulse generator; it modulates a circuit and does not cure the underlying disorder.
Selection is diagnosis-specific. In Parkinson's disease, NICE says not to offer DBS when best medical therapy adequately controls symptoms and to consider it when advanced disease remains inadequately controlled.
A multidisciplinary team defines target symptoms, confirms treatment refractoriness and assesses cognition, mood, gait, levodopa response, medical fitness, support and the person’s ability to manage follow-up.
Key red flags
Acute focal deficit, severe headache, seizure or depressed consciousness during or after implantation requires immediate intracranial-haemorrhage and stroke assessment.
Fever, wound pain, redness, erosion or discharge anywhere along the lead, extension or pulse-generator track suggests hardware infection and needs urgent specialist review.
Sudden loss of benefit should trigger safe device-state, battery, impedance and medication review before it is labelled disease progression.
New impulsivity, depression, suicidality, confusion, troublesome dysarthria or gait freezing after programming needs prompt multidisciplinary reassessment rather than repeated unsupervised amplitude increases.
Postoperative emergency
New neurological deficit, seizure, reduced consciousness, fever or wound drainage after implantation requires urgent neurosurgical assessment.
Reasoning priorities
01
Disorder-specific specialist assessment and treatment-response diary
Confirm diagnosis, quantify disability and determine which symptoms improve with established therapy and are realistic DBS targets.
A strong levodopa response in Parkinson's disease supports potential motor benefit, but gait, speech, cognition and non-motor outcomes require separate prediction.
Worked reasoning
Worked caseAdvanced Parkinson motor fluctuations
Levodopa-responsive fluctuations or tremor remain disabling despite optimised therapy and the person requests an advanced option.
Refer to a specialist movement-disorder MDT; document best medical therapy, response profile, off-state disability, dyskinesia, gait, speech, cognition, mood, comorbidity and patient goals.
Explain that assessment compares DBS with infusion and continuing medical options; identify target symptoms and outcomes that DBS is unlikely to improve.
If selected, complete consent, device and imaging planning, perioperative medicine coordination and a postoperative programming plan.
Review motor and non-motor outcome against baseline while adjusting stimulation and medication together rather than pursuing a single score.
TroubleshootingAbrupt return of treated symptoms
Previously stable benefit is lost suddenly without a new neurological emergency.
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 13 Sept 2026; clinical approval remains outstanding.
NICE NG71 Parkinson's disease in adultsPublished 19 July 2017; current recommendations body read 13 September 2026. Scope; advanced therapies and deep-brain-stimulation recommendations; information, multidisciplinary care and non-motor symptom sections. Supports: Do not offer DBS when symptoms are adequately controlled by best medical therapy; consider it for advanced Parkinson's disease inadequately controlled by best medical therapy. Limits: Adults with Parkinson's disease in UK NHS care; it does not define DBS eligibility for essential tremor, dystonia, epilepsy or psychiatric disease. Chapter-specific use: deep-brain-stimulation-principles.
NICE HTG7 deep brain stimulation for Parkinson's diseaseOriginally published 26 November 2003; current migrated HealthTech guidance body read 13 September 2026. Recommendations 1.1 to 1.3 and procedure safety summary. Supports: Governance, consent, audit and multidisciplinary selection for disease refractory to best medical treatment. Limits: Interventional-procedure evidence for Parkinson's disease; current clinical selection should be read with NG71. Chapter-specific use: deep-brain-stimulation-principles.
Identification and management of DBS urgencies and emergenciesParkinsonism & Related Disorders review published 2010; relevant full-text sections read 13 September 2026. Hardware malfunction; accidental on/off; symptom rebound; Table 2 postoperative urgency and emergency management. Supports: Abrupt loss of established benefit warrants checking whether the device is on, using the patient remote/controller, and a DBS hardware work-up including battery and impedance checks; imaging follows when a structural fault remains possible. Limits: Professional review centred on movement-disorder DBS and older Medtronic-era systems; exact controller functions, alert thresholds, programming and imaging conditions remain manufacturer- and model-specific. Chapter-specific use: deep-brain-stimulation-principles.
NICE HTG122 DBS for tremor and dystonia excluding Parkinson's diseasePublished 23 August 2006; current migrated HealthTech body read 13 September 2026. Indications 2.1.1 to 2.1.5; procedure; efficacy and safety sections. Supports: Disease-specific separation of severe disabling refractory tremor and dystonia from Parkinson's disease, and recognised procedural risks. Limits: Excludes Parkinsonian tremor and dystonia; older interventional guidance does not substitute for contemporary disorder-specific MDT assessment. Chapter-specific use: deep-brain-stimulation-principles.